| 1 |
severe acute respiratory syndrome coronavirus 2
(17042 times)
|
Medicine
(1628 times)
|
COVID-19 (8380 times)
ACE2 (951 times)
RT-PCR (668 times)
|
2020 Challenges to the system of reserve medical supplies for public health emergencies: reflections on the outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic in China.
|
| 2 |
syndrome coronavirus 2
(242 times)
|
Medicine
(24 times)
|
COVID-19 (111 times)
ACE2 (16 times)
RT-PCR (10 times)
|
2020 Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19.
|
| 3 |
SARS coronavirus 2
(133 times)
|
Medicine
(15 times)
|
COVID-19 (51 times)
SARS (24 times)
ACE2 (18 times)
|
2020 SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
|
| 4 |
Since December 2019, novel coronavirus
(9 times)
|
Allergy and Immunology
(1 time)
|
AUC (1 time)
BMI (1 time)
COVID-19 (1 time)
|
2020 The liver injury and gastrointestinal symptoms in patients with Coronavirus Disease 19: A systematic review and meta-analysis.
|
| 5 |
Sequence of a 2019 Novel Coronavirus
(8 times)
|
Microbiological Phenomena
(5 times)
|
COVID-19 (3 times)
HLH (1 time)
|
2020 Complete Genome Sequence of a 2019 Novel Coronavirus (SARS-CoV-2) Strain Isolated in Nepal.
|
| 6 |
syndrome coronavirus 2 infection
(6 times)
|
Nursing
(1 time)
|
COVID-19 (1 time)
ED (1 time)
GBS (1 time)
|
2020 SARS-CoV-2 and Guillain-Barre syndrome: AIDP variant with a favourable outcome.
|
| 7 |
syndrome-corona virus 2
(5 times)
|
Public Health
(1 time)
|
COVID-19 (1 time)
LMWH (1 time)
N-protein (1 time)
|
2020 COVID-19, coagulopathy and venous thromboembolism: more questions than answers.
|
| 8 |
SARS-associated coronavirus type 2
(3 times)
|
Pharmacology
(1 time)
|
COVID-19 (2 times)
ARDS (1 time)
DAD (1 time)
|
2021 The Large Action of Chlorpromazine: Translational and Transdisciplinary Considerations in the Face of COVID-19.
|
| 9 |
severe acute respiratory virus 2
(3 times)
|
Neoplasms
(1 time)
|
ACE2 (1 time)
AKI (1 time)
APOL1 (1 time)
|
2021 Severe Neurologic Complications of SARS-CoV-2.
|
| 10 |
severe acute syndrome coronavirus 2
(3 times)
|
Cell Biology
(1 time)
|
ACE-2 (1 time)
ACE2 (1 time)
ATII (1 time)
|
2020 Potential role for tissue factor in the pathogenesis of hypercoagulability associated with in COVID-19.
|
| 11 |
anti-SARScoronavirus-2
(2 times)
|
Communicable Diseases
(1 time)
|
MIS-C (1 time)
NAb (1 time)
|
2021 COVID-19-Related Potential Multisystem Inflammatory Syndrome in Childhood in a Neonate Presenting as Persistent Pulmonary Hypertension of the Newborn.
|
| 12 |
severe acute coronavirus type 2
(2 times)
|
Pediatrics
(1 time)
|
COVID-19 (2 times)
|
2020 Acral lesions in a pediatric population during the COVID-19 pandemic: a case series of 36 patients from a single hospital in Spain.
|
| 13 |
severe acute respiratory infections caused by 2019 novel coronavirus
(2 times)
|
Allergy and Immunology
(1 time)
|
---
|
2020 Current perspective on diagnosis, epidemiological assessment, prevention strategies, and potential therapeutic interventions for severe acute respiratory infections caused by 2019 novel coronavirus (SARS-CoV-2).
|
| 14 |
stages of the novel coronavirus 2019
(2 times)
|
Allergy and Immunology
(2 times)
|
SEAIC (2 times)
STD (2 times)
HCP (1 time)
|
2021 High frequency of smell and taste dysfunctions in allergy health care professionals suffering from COVID-19.
|
| 15 |
Subsequently, coronavirus 2
(2 times)
|
Medicine
(2 times)
|
IL (2 times)
COVID-19 (1 time)
|
2020 COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs
|
| 16 |
suggested that infections with Coronavirus 2
(2 times)
|
Medicine
(1 time)
|
---
|
2021 Hashimoto's thyroiditis following SARS-CoV-2 infection.
|
| 17 |
syndrome related to coronavirus-2
(2 times)
|
Allergy and Immunology
(1 time)
|
COVID-19 (2 times)
|
2020 Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review.
|
| 18 |
syndrome that is caused by a novel coronavirus 2
(2 times)
|
|
COVID-19 (1 time)
|
2020 Targeting SARS-CoV-2 receptors as a means for reducing infectivity and improving antiviral and immune response: an algorithm-based method for overcoming resistance to antiviral agents.
|
| 19 |
syndrome type 2 coronavirus
(2 times)
|
Skin Diseases
(1 time)
|
NAAT (1 time)
|
2021 Epidemiological study in a small rural area of Veneto (Italian region) during Sars-Cov-2 Pandemia.
|
| 20 |
Syndrome-related Coronavirus type 2
(2 times)
|
Cognitive Science
(1 time)
|
COVID-19 (1 time)
COVID-2019 (1 time)
PA (1 time)
|
2021 COVID-19 Pandemic and Physical Exercise: Lessons Learnt for Confined Communities.
|
| 21 |
coronavirus-Severe Acute Respiratory Syndrome-Coronavirus 2
(1 time)
|
|
COVID-19 (1 time)
|
2021 A Perspective on COVID-19 Management.
|
| 22 |
SARS coronavirus type 2
(1 time)
|
Virology
(1 time)
|
---
|
2021 Retrospective screening of routine respiratory samples revealed undetected community transmission and missed intervention opportunities for SARS-CoV-2 in the United Kingdom.
|
| 23 |
SARS memory on the public awareness of 2019 novel coronavirus
(1 time)
|
Natural Science Disciplines
(1 time)
|
---
|
2020 The impact of social ties and SARS memory on the public awareness of 2019 novel coronavirus (SARS-CoV-2) outbreak.
|
| 24 |
SARS-like coronavirus 2
(1 time)
|
Molecular Biology
(1 time)
|
ACE2 (1 time)
COVID-19 (1 time)
RBM (1 time)
|
2021 Possible inhibition of GM-CSF production by SARS-CoV-2 spike-based vaccines.
|
| 25 |
SARS-related coronavirus-2
(1 time)
|
Aging
(1 time)
|
FDA (1 time)
|
2021 Global Sex Disparity of COVID-19: A Descriptive Review of Sex Hormones and Consideration for the Potential Therapeutic Use of Hormone Replacement Therapy in Older Adults.
|
| 26 |
Scholar, from February to October 5, 2020, focusing on COVID-19
(1 time)
|
Dentistry
(1 time)
|
ACE2 (1 time)
|
2021 Oral mucosal lesions and oral symptoms of the SARS-CoV-2 infection.
|
| 27 |
Secondary to Coronavirus 2
(1 time)
|
Occupational Health
(1 time)
|
COVID-19 (1 time)
FDA (1 time)
PEEP (1 time)
|
2020 Severe Acute Respiratory Distress Syndrome Secondary to Coronavirus 2 (SARS-CoV-2).
|
| 28 |
Semester of 2020, an outbreak of a novel coronavirus
(1 time)
|
Ecological and Environmental Phenomena
(1 time)
|
---
|
2021 Lessons learned through listening to biology students during a transition to online learning in the wake of the COVID-19 pandemic.
|
| 29 |
Sensitivity evaluation of 2019 novel coronavirus
(1 time)
|
Medicine
(1 time)
|
---
|
2020 Sensitivity evaluation of 2019 novel coronavirus (SARS-CoV-2) RT-PCR detection kits and strategy to reduce false negative.
|
| 30 |
series of two patients with laboratory-confirmed coronavirus 2
(1 time)
|
Clinical Medicine
(1 time)
|
---
|
2021 Theophylline in Treatment of COVID-19 Induced Sinus Bradycardia.
|
| 31 |
serious respiratory condition created by the coronavirus 2
(1 time)
|
Clinical Medicine
(1 time)
|
---
|
2020 Credible Protein Targets and Curative Strategies for COVID-19: a Review.
|
| 32 |
serological test in the diagnosis of 2019 novel coronavirus
(1 time)
|
Communicable Diseases
(1 time)
|
SARS-CoV (1 time)
|
2020 Evaluations of the serological test in the diagnosis of 2019 novel coronavirus (SARS-CoV-2) infections during the COVID-19 outbreak.
|
| 33 |
Services and the Field Hospital Experience During Coronovirus Disease 2019
(1 time)
|
Military Medicine
(1 time)
|
JNYMS (1 time)
NYC (1 time)
|
2021 Uniformed Services and the Field Hospital Experience During Coronovirus Disease 2019 (SARS-CoV-2) Pandemic: Open to Closure in 30 Days With 1,100 Patients: The Javits New York Medical Station.
|
| 34 |
severe acute respiratory CoV-2
(1 time)
|
Microbiology
(1 time)
|
CoV (1 time)
|
2021 Replicative Fitness of a SARS-CoV-2 20I/501Y.V1 Variant from Lineage B.1.1.7 in Human Reconstituted Bronchial Epithelium.
|
| 35 |
severe acute respiratory illness caused by the coronavirus 2
(1 time)
|
Aging
(1 time)
|
ASCs (1 time)
COVID-19 (1 time)
MSCs (1 time)
|
2020 Adipose Stem Cells (ASCs) and Stromal Vascular Fraction (SVF) as a Potential Therapy in Combating (COVID-19)-Disease.
|
| 36 |
Severe acute respiratory infection Coronavirus 2
(1 time)
|
Advanced Practice Nursing
(1 time)
|
---
|
2021 Correct Execution of the Nasopharyngeal Swab: A Fundamental Method to Improve Diagnosis of SARS-CoV-2 Infection.
|
| 37 |
severe cases of coronavirus 2
(1 time)
|
Pharmacology
(1 time)
|
---
|
2021 Remdesivir; molecular and functional measures of mitochondrial safety.
|
| 38 |
severe disease and cardiac injury incorona virus 2
(1 time)
|
Diabetes Complications
(1 time)
|
ACE2 (1 time)
ACEi (1 time)
ARBs (1 time)
|
2021 Expression of the SARS-CoV-2 receptorACE2 in human heart is associated with uncontrolled diabetes, obesity, and activation of the renin angiotensin system.
|
| 39 |
severe infection with the new coronavirus2
(1 time)
|
Otolaryngology
(1 time)
|
PAPR (1 time)
PEEP (1 time)
PPE (1 time)
|
2021 Surgical tracheostomy in acohort of COVID-19patients.
|
| 40 |
Severe Acute Respiratory Syndrome Coronavirus 2
(1 time)
|
Virology
(1 time)
|
VOC (1 time)
|
2021 Antiviral Effect of Budesonide against SARS-CoV-2.
|
| 41 |
sickness coronavirus 2
(1 time)
|
Molecular Biology
(1 time)
|
---
|
2020 Is BCG vaccination causally related to reduced COVID-19 mortality?
|
| 42 |
similarity between syndrome coronavirus 2
(1 time)
|
Biology
(1 time)
|
COVID-19 (1 time)
|
2021 Advances, challenges and opportunities of phylogenetic and social network analysis using COVID-19 data.
|
| 43 |
Since December 2019, a number of patients infected with COVID-19
(1 time)
|
Pediatrics
(1 time)
|
---
|
2020 Analysis and suggestions for the preview and triage screening of children with suspected COVID-19 outside the epidemic area of Hubei Province.
|
| 44 |
Since December 2019, COVID-19, caused by the new coronavirus
(1 time)
|
Medicine
(1 time)
|
CNKI (1 time)
REDI (1 time)
XFF (1 time)
|
2020 The curative effect of Reduning injection combined with Xuanfeibaidu formula on COVID-19: A protocol for systematic review and meta-analysis.
|
| 45 |
Since December 2019, pneumonia caused by a novel coronavirus
(1 time)
|
Medicine
(1 time)
|
CRP (1 time)
CT (1 time)
ESR (1 time)
|
2021 Clinical characteristics, treatment, and prognosis of 74 2019 novel coronavirus disease patients in Hefei: A single-center retrospective study.
|
| 46 |
Since in late 2019, when the coronavirus 2
(1 time)
|
|
COVID-19 (1 time)
|
2021 Food Containing Bioactive Flavonoids and Other Phenolic or Sulfur Phytochemicals With Antiviral Effect: Can We Design a Promising Diet Against COVID-19?
|
| 47 |
Since the outbreak of 2019 novel coronavirus
(1 time)
|
Virology
(1 time)
|
COVID-19 (1 time)
IL (1 time)
ILD (1 time)
|
2020 Clinical characteristics of COVID-19 in patients with preexisting ILD: A retrospective study in a single center in Wuhan, China.
|
| 48 |
Since the outbreak of the new coronavirus in 2019
(1 time)
|
Cell Death
(1 time)
|
COVID-19 (1 time)
|
2020 SARS-CoV-2 infection: can ferroptosis be a potential treatment target for multiple organ involvement?
|
| 49 |
site of infection with Coronavirus-2
(1 time)
|
Optometry
(1 time)
|
ACE2 (1 time)
COVID-19 (1 time)
|
2020 The ocular surface, coronaviruses and COVID-19.
|
| 50 |
specific against the novel coronavirus 2019
(1 time)
|
Chemistry Techniques, Analytical
(1 time)
|
DBS (1 time)
SPR (1 time)
|
2021 Cross-validation of ELISA and a portable surface plasmon resonance instrument for IgG antibody serology with SARS-CoV-2 positive individuals.
|
| 51 |
spread of public awareness of the 2019 novel coronavirus
(1 time)
|
Natural Science Disciplines
(1 time)
|
---
|
2020 The impact of social ties and SARS memory on the public awareness of 2019 novel coronavirus (SARS-CoV-2) outbreak.
|
| 52 |
strategies for coronavirus 2
(1 time)
|
Medicine
(1 time)
|
COVID-19 (1 time)
MEURI (1 time)
|
2020 An overview of antiviral strategies for coronavirus 2 (SARS-CoV-2) infection with special reference to antimalarial drugs chloroquine and hydroxychloroquine.
|
| 53 |
Strategies to halt 2019 novel coronavirus
(1 time)
|
Transplantation
(1 time)
|
---
|
2020 Strategies to halt 2019 novel coronavirus (SARS-CoV-2) spread for organ transplantation programs at the Sichuan Academy of Medical Science and Sichuan Provincial People's Hospital, China.
|
| 54 |
study of 289 patients diagnosed with 2019 Novel Coronavirus
(1 time)
|
Cardiology
(1 time)
|
ICU (1 time)
|
2021 Renin-angiotensin System Blocker in COVID-19. A Single Center Study.
|
| 55 |
Study on Knowledge, Behavior, and Attitude Toward Novel Coronavirus 2019
(1 time)
|
Public Health
(1 time)
|
---
|
2020 A Study on Knowledge, Behavior, and Attitude Toward Novel Coronavirus 2019 (SARS-CoV-2) Among the Jordanian Population.
|
| 56 |
subsequently defined as the new coronavirus of 2019
(1 time)
|
Medicine
(1 time)
|
ICU (1 time)
|
2020 [Intensive care during the 2019-coronavirus epidemic].
|
| 57 |
such as corona virus-2
(1 time)
|
Pharmacology
(1 time)
|
EGCG (1 time)
HIV (1 time)
|
2021 A Review of Medicinal Plants with Antiviral Activity Available in Bangladesh and Mechanistic Insight Into Their Bioactive Metabolites on SARS-CoV-2, HIV and HBV.
|
| 58 |
such as the coronavirus 2
(1 time)
|
Environmental Health
(1 time)
|
---
|
2020 A Systems Approach to Assess Transport and Diffusion of Hazardous Airborne Particles in a Large Surgical Suite: Potential Impacts on Viral Airborne Transmission.
|
| 59 |
surfaces used by health care workers and patients in coronavirus-2
(1 time)
|
Environmental Health
(1 time)
|
---
|
2021 Evaluation of masks' internal and external surfaces used by health care workers and patients in coronavirus-2 (SARS-CoV-2) wards.
|
| 60 |
suspected for novel Coronavirus 2019
(1 time)
|
Radiology
(1 time)
|
---
|
2020 Diagnostic impact of bedside chest X-ray features of 2019 novel coronavirus in the routine admission at the emergency department: case series from Lombardy region.
|
| 61 |
sustained by the 2019 novel coronavirus
(1 time)
|
Chemistry, Clinical
(1 time)
|
FDP (1 time)
FIB (1 time)
PT-act (1 time)
|
2020 Prominent changes in blood coagulation of patients with SARS-CoV-2 infection.
|
| 62 |
swab for 2019-novel coronavirus
(1 time)
|
General Surgery
(1 time)
|
---
|
2020 Performing the nasopharyngeal and oropharyngeal swab for 2019-novel coronavirus (SARS-CoV-2) safely: How to dress, undress, and technical notes.
|
| 63 |
syndrome coranovirus-2 virus
(1 time)
|
Gynecology
(1 time)
|
ARDS (1 time)
COVID-19 (1 time)
|
2021 COVID-19 impact on perinatal care: risk factors, clinical manifestation and prophylaxis. Polish experts' opinion for December 2020.
|
| 64 |
syndrome coronavirus 2-associated
(1 time)
|
|
COVID-19 (1 time)
SNP (1 time)
|
2021 Associations between Allelic Variants of the Human IgH 3' Regulatory Region 1 and the Immune Response to BNT162b2 mRNA Vaccine.
|
| 65 |
Syndrome Coronavirus Disease 2019
(1 time)
|
Public Health
(1 time)
|
LTCFs (1 time)
|
2021 The Main Issues and Challenges Older Adults Face in the SARS-CoV-2 Pandemic: A Scoping Review of Literature.
|
| 66 |
Syndrome disease caused by Coronavirus-2
(1 time)
|
Pharmacology
(1 time)
|
---
|
2021 Giloy Ghanvati (Tinospora cordifolia (Willd.) Hook. f. and Thomson) Reversed SARS-CoV-2 Viral Spike-Protein Induced Disease Phenotype in the Xenotransplant Model of Humanized Zebrafish.
|
| 67 |
syndrome has been classified as a corona virus 2
(1 time)
|
Environmental Health
(1 time)
|
COVID-19 (1 time)
PHEIC (1 time)
|
2021 Environmental and health impacts of spraying COVID-19 disinfectants with associated challenges.
|
| 68 |
syndrome, associated with coronavirus 2
(1 time)
|
Clinical Trials as Topic
(1 time)
|
COVID-19 (1 time)
|
2021 Doxycycline in the Coronavirus Disease 2019 Therapy.
|
| 69 |
syndrome-associated coronavirus-2
(1 time)
|
General Surgery
(1 time)
|
COVID-19 (1 time)
|
2021 Intestinal Abnormalities in Patients With SARS-CoV-2 Infection: Histopathologic Changes Reflect Mechanisms of Disease.
|
| 70 |
syndrome-related coronavirus-2, the viral pathogen causing COVID-19 disease
(1 time)
|
|
COVID-19 (1 time)
SIR (1 time)
|
2020 Creating and applying SIR modified compartmental model for calculation of COVID-19 lockdown efficiency.
|
A Search Service for Abbreviation / Long Form